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Abstract
This population-based study used administrative healthcare data to examine the uptake of
tests recommended for colorectal cancer screening by eligible Ontario physicians and
non-physicians, and to examine if testing of primary care physicians is associated with
greater testing in their patients. Physicians (n=11,434) were matched 1:4 to nonphysicians (n=45,736) on age, sex, and geographic location as of April 21, 2016. Uptake
of colorectal tests was similar in physicians (67.9%, 95% CI, 67.0–68.7%) and nonphysicians (66.6%, 95% CI, 66.2–67.1%). Physicians were more likely than nonphysicians to undergo colonoscopy and less likely to undergo fecal occult blood testing.
Uptake of colorectal tests by primary care physicians was associated with greater testing
in their patients (adjusted prevalence ratio, 1.10; 95% CI, 1.08–1.12). These results
highlight the opportunity for greater screening of physicians, who may in turn positively
influence screening in their patients.

Keywords
Colorectal cancer, cancer screening, secondary prevention, public health, physician
health, fecal occult blood test, flexible sigmoidoscopy, colonoscopy.
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Lay summary
This study used several databases to examine the uptake of colorectal cancer screening
among 11,434 physicians and 45, 736 screen-eligible non-physicians in Ontario. Overall
uptake of colorectal tests was similar in physicians (67.9%) and non-physicians (66.6%).
Physicians were more likely than non-physicians to undergo colonoscopy and less likely
to undergo fecal occult blood testing. Patients were also more likely to be tested if their
family physician was tested. These results highlight the opportunity for greater screening
of physicians, who may in turn positively influence screening in their patients.
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Chapter 1
1 Introduction
Colorectal cancer is a significant source of morbidity and mortality in Canada, accounting
for 13% of all cancers nationally, and 12% of all cancer deaths (26,800 cases and 9,400
deaths in 2017).1 Fortunately, several screening tests are available that have been
demonstrated to reduce colorectal cancer mortality.2–4 While recommendations for
screening average-risk individuals vary by country, most guidelines recommend a fecal
occult blood test (FOBT) every 1–2 years, and some recommend flexible sigmoidoscopy
every five years or colonoscopy every ten years (recommendations from six organizations
are summarized in Table 1.2,5–11
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Table 1: Recommendations for colorectal cancer screening in average-risk individuals.

*Insufficient evidence to recommend the inclusion or exclusion of this screening modality for colorectal cancer.
†Canadian Task Force on Preventive Health Care. Colorectal cancer screening. Recommendation statement from the
Canadian Task Force on Preventive Health Care. CMAJ. 2001;165:206-208.
‡ Canadian Task Force on Preventive Care. Recommendations on screening for colorectal cancer in primary
care. CMAJ. 2016;188:340-348.
§ Cancer Care Ontario. ColonCancerCheck (CCC) Screening Recommendations Summary—April
2016. www.cancercareontario.ca/sites/ccocancercare/files/assets/CCCScreeningRecommendations.pdf.
∥ U.S. Preventive Services Task Force. Screening for Colorectal Cancer: U.S. Preventive Services Task Force
Recommendation Statement. Ann Intern Med. 2008;149:627.
¶ U.S. Preventive Services Task Force. Screening for Colorectal Cancer US Preventive Services Task Force
Recommendation Statement. JAMA. 2016;315:2564-2575.
** National Health Service. Bowel cancer screening. 2015. www.nhs.uk/conditions/bowel-cancer-screening/.
††Australian Government Department of Health. National Bowel Cancer Screening Program.
2015. www.health.gov.au/internet/screening/publishing.nsf/Content/bowel-screening-1.
‡‡ National Screening Service. Bowel Screening. 2012. www.screeningservice.ie/bowel-screening.html

3
Despite the evidence in support of routine colorectal cancer screening, physician support
for screening remains variable.12–15 For instance, a survey of family physicians in
Saskatchewan found that although 87.5% of physicians believe that colorectal cancer
screening is beneficial in people without a family history of colorectal cancer, only 77%
of physicians routinely recommend screening for patients without a family history of
colorectal cancer.13 This variable physician support for screening has important
implications given that population-level screening participation in Ontario is consistently
suboptimal (approximately 30% participation for FOBT).16 Strategies to increase
provincial screening participation, including public media awareness campaigns and the
use of pay-for-performance incentives for physicians, have unfortunately not resulted in a
sustained increase in screening.17,18
There is evidence that when physicians are compliant with cancer screening
recommendations, their patients are significantly more likely to be compliant too,19 and
this represents a unique opportunity for physicians to lead from the front in cancer
prevention. However, most studies of physicians’ personal screening behaviors consist of
surveys that may be limited by recall and social desirability biases.14,15,20,21 Indeed, there
has never been a comprehensive analysis of a group of North American physicians’
screening behaviors assessing the actual tests they had performed.
We used health administrative data to conduct a population-based, cross-sectional study,
with the aim of comparing uptake of colorectal tests in physicians and non-physicians in
Ontario. We also aimed to identify and quantify physician characteristics that are
associated with testing, and to determine whether patients are more likely to undergo
testing when their own family physician is tested.
The following thesis consists of six chapters. Chapter 2 contains a review of the relevant
cancer screening literature. Chapter 3 contains the rationale for investigating cancer
testing uptake in physicians, as well as the specific objectives and hypotheses of this
thesis. Chapter 4 describes the methodology used to address the objectives. Chapter 5
contains the results of the analysis, and Chapter 6 contains a discussion and interpretation
of the findings, and suggestions for future studies.
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Chapter 2
2 Literature Review
A review of English language scientific articles was conducted. This literature review
included evidence cited in guidelines and systematic reviews from the Canadian Task
Force on Preventive Health Care (CTFPHC), Cancer Care Ontario and the United States
Preventive Services Task Force (USPSTF), as well as articles identified through
searching PubMed and Google Scholar, and from searching the reference lists of articles
cited by the aforementioned organizations.

2.1 Colorectal cancer
Colorectal cancer is the 2nd most frequently diagnosed cancer in Ontario. In 2017 there
were 10,400 new colorectal cancer diagnoses (5,700 men and 4,700 women), and it
caused 3,250 deaths (1,750 men, and 1,500 women).1
In Ontario between 1982 and 2012, the age-standardized incidence rate of colorectal
cancer in males decreased from 82.1 per 100,000 to 80.2 per 100,000, and, among
females, decreased from 65.3 per 100,000 to 57.7 per 100,000. During this time, the agestandardized colorectal cancer mortality rate among males decreased from 46 per 100,000
to 29 per 100,000, and, among females, decreased from 34.2 per 100,000 to 18.2 per
100,000.
One of the established risk factors for colorectal cancer is older age, as 93% of cases are
diagnosed in people age 50 or older.22 Other non-modifiable risk factors include having a
personal or family history of colorectal cancer, inflammatory bowel disease, or colorectal
polyps.23–25 Having a first-degree relative with a history of colorectal cancer is associated
with a two to three-fold increased risk of developing colorectal cancer.26 Modifiable risk
factors for colorectal cancer include a high intake of processed and red meat, low fiber
intake, obesity, diabetes, physical inactivity, as well as tobacco and alcohol use.23–25,27
Colorectal cancer begins as an adenomatous polyp in the lumen of the colon or rectum.28
Genetic mutations and abnormal cell divisions can result in formation of a polyp.
Colorectal polyps are relatively common, and one chart review found that 58% of

5
asymptomatic patients aged 50-59 had a colorectal polyp found using colonoscopy.29
Moreover, the 10-year cumulative risk of cancerous transformation of polyps is 25% (in a
55 year old),30 and pre-cancerous polyps generally take 10 to 15 years to transform into
adenocarcinomas.31
Symptoms of colorectal cancer may include weight loss, blood in the stool, fatigue,
bowel movement irregularities, and a change in the shape and consistency of stool.23,24
The presence of these symptoms, or other findings that result in a high index of suspicion
of colorectal cancer should prompt an intensive diagnostic work-up, usually consisting of
endoscopy followed by the histologic analysis of a colorectal biopsy sample.31 Treatment
options for colorectal cancer are tailored to individual patients, and may include
colorectal resection (most common initial treatment modality), potentially followed by
chemotherapy, and external radiation beam therapy.23,24 The prognosis for colorectal
cancer is lower than the prognosis for breast or cervical cancer: the five-year agestandardized net survival in Canada is 64%.1

2.2 Principles of screening
The goal of screening for a disease is to prevent morbidity and mortality due to that
particular disease. Cancer screening is categorized as a type of secondary prevention,
meaning that the goal is to identify cancer early in the course of disease (pre-cancerous
colorectal polyps) and to afford an opportunity for subsequent interventions to prevent
disease progression (e.g. removal of the polyps in a procedure called a polypectomy). In
contrast, primary prevention includes interventions in people who do not have the disease
in question (chickenpox vaccination for people without prior exposure to varicella zoster
virus), while tertiary prevention aims to reduce the impact of disease symptoms on one’s
life, as in the use of beta blockers post-myocardial infarction.32
Organized screening is characterized by a central coordination of screening efforts. This
includes screening invitations and follow-up after screening. An example of this is
Ontario’s Colon Cancer Check program, which launched in 2008. Conversely, in
opportunistic screening, there is no centralized coordination of screening, and screening
tests are ordered at the discretion of one’s physician. Prior to 2008, colorectal cancer
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screening in Ontario was done opportunistically. Screening high-risk individuals often
involves more frequent screening, and the use of different screening modalities. For
example, magnetic resonance imaging is used to supplement mammography in the highrisk Ontario Breast Screening Program, whereas women at average-risk of breast cancer
only receive mammography. Lastly, mass screening involves screening of people without
regard for risk profiles, an example of which is screening for hypertension in all adults
(age>18) at periodic health examinations.
There are several factors that determine whether a screening test will be effective when
used in the general public.33 These factors are known as Wilson’s criteria, which consist
of the following 10 requirements: 1) the condition should be an important health problem,
2) there should be a treatment for the condition, 3) facilities for diagnosis and treatment
should be available, 4) there should be a latent stage of the disease that cannot be detected
by means other than screening (i.e. if all colorectal polyps caused symptoms, then all
patients with polyps would be worked-up with diagnostic testing, which would negate the
need for screening), 5) there should be a reliable test or examination for the condition, 6)
the test should be acceptable to the population, 7) the natural history of the disease should
be adequately understood, 8) there should be an agreed policy on whom to treat, 9) the
total cost of finding a case should be economically balanced in relation to medical
expenditure as a whole, and 10) case-finding should be a continuous process in all
eligible individuals, and should be actively promoted.
Important operating characteristics of screening tests include sensitivity and specificity.
Sensitivity is the probability that the test will be positive in people with the disease being
screened, whereas specificity is the probability of a negative test in people without the
disease.32 For screening tests, high test sensitivity will enable clinicians to exclude
diagnoses in non-diseased people. Conversely, high test specificity will enable clinicians
to confirm diagnoses in people with the disease being investigated. Sensitivity and
specificity are inherent characteristics of a test, and do not depend on the prevalence of
the disease in the screen-eligible population.
Sometimes false positive and false negative test results occur, and this has serious

7
implications for patient care.23 Consequences of a false-positive test result may lead to
increased anxiety after receiving a positive test result and undergoing unnecessary
diagnostic testing and treatment. Conversely, the implications of a false-negative result
may include delayed diagnosis, greater disease progression, and more extensive treatment
required for a more advanced disease.
Another important characteristic of screening tests is the number needed to screen (NNS).
This measure indicates the number of people who need to be screened in order to prevent
a death due to the disease.

2.3 Colorectal cancer testing modalities
There are three main tests used for colorectal cancer screening: FOBT, flexible
sigmoidoscopy, and colonoscopy. While recommendations for screening average-risk
individuals vary by country, most guidelines recommend an FOBT every 1–2 years, and
some recommend flexible sigmoidoscopy every five years or colonoscopy every ten years
(recommendations from six organizations are summarized in Table 1). These tests are
discussed in section 2.3.1 to 2.3.4, and guidelines are discussed in sections 2.4 and 2.5.

2.3.1 Fecal occult blood tests
Colorectal cancer screening tests such as FOBTs are used to detect lesions in the large
intestine and rectum.23,24 FOBT identifies hemoglobin in the stool, which may be present
due to ruptured vasculature on the surface of polyps or carcinomas, and a positive finding
would be an indication for further investigations to determine whether an individual has
any gastrointestinal pathology.23,24,34 Guaiac FOBTs (gFOBT) can be completed in
patients’ homes, and involves collecting a series of stool samples and placing them onto
the surface of absorbent, guaiac-embedded paper.34,35 Upon exposure to hydrogen
peroxide, the presence of occult blood in the stool will cause the guaiac-paper to turn blue
due to the peroxidase activity of hemoglobin.23,24,34
The CTFPHC conducted a meta-analysis of four moderate quality RCTs with a combined
sample size of 313,180 that showed a significant decrease in colorectal cancer mortality
for individuals who were randomized to receive a FOBT vs no screening (RR 0.82 [95%
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CI 0.73-0.92]).23 The CTFPHC also conducted a meta-analysis of two moderate quality
RCTs (combined sample size of 220,283) and found a significant decrease in the
incidence of late-stage colorectal cancer for individuals who were randomized to receive
an FOBT vs no screening (RR 0.92 [95% CI 0.85-0.99]).23 Additionally, the CTFPHC
examined a number of studies and found that the median sensitivity of gFOBT was
47.1%, and the median specificity was 96.1%. For this test, the mean NNS to prevent one
death from colorectal cancer is 597.23 In comparison, for mammography, the mean NNS
in women aged 50-59 to prevent one breast cancer death is 1,500, and to prevent one
death from melanoma, 25,000 people would need to undergo a whole-body skin check.36
There is no direct risk associated with the FOBT given that it is a non-invasive test.
However, there is a risk of receiving a false-positive result that could lead to unnecessary
invasive procedures, such as colonoscopy or biopsy. Specifically, one study found that
after 10 years of annual FOBTs, the probability of having a false-positive result was
23.0% (95% CI 18.2%-27.0%).37 Dietary and medication restrictions in the 72 hours prior
to stool collection for FOBT are important in order to avoid false-positive and falsenegative FOBT results. False positives may be increased in patients who consume red
meat, turnips, broccoli, cauliflower, and radishes.38 Food and drinks containing vitamin C
should also be avoided in order to avoid false negatives. It is less clear as to whether
aspirin should be withheld prior to stool collection to minimize the possibility of a false
positive result.39
A number of barriers to undergoing FOBTs have been identified in the literature, and
these include a fear of handling stool, confusion regarding how to conduct FOBTs,
logistical issues surrounding the shipping and storage of stool samples, and the need for
follow-up testing if the FOBT yields a positive result.40
Related to FOBT is fecal immunochemical testing (FIT), which is an assay that uses an
antibody that specifically detects human hemoglobin. FIT is more sensitive and specific
than FOBT and does not require any dietary restrictions in the 72 hours before stool
collection, unlike FOBT. FIT is also faster to complete than FOBT, as it only requires a
single stool collection, whereas FOBT requires stool collection on three separate
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occasions.

2.3.2 Flexible sigmoidoscopy
Flexible sigmoidoscopy is a form of lower bowel endoscopy that is used to directly
visualize the anus, rectum, sigmoid colon and descending colon (up to the splenic
flexure), and may be used to identify lesions and perform biopsies.5,23 The CTFPHC
conducted a meta-analysis of four RCTs to assess the impact of receiving a flexible
sigmoidoscopy (versus no screening) on colorectal cancer mortality. The combined
sample size of the RCTs was 413,955 and there was a significant decrease in colorectal
cancer mortality for those who were randomized to receive a flexible sigmoidoscopy
compared to those who were not (RR 0.72 [95% CI 0.65-0.81]), and the NNS was 850.23
The sensitivity of flexible sigmoidoscopy was estimated to be 40-60%, and the specificity
was estimated to be 94%.41
Another meta-analysis of three RCTs with a combined sample size of 243,917 examined
the impact of flexible sigmoidoscopy (compared with no screening) on the incidence of
late-stage colorectal cancer and found a significant decrease in the incidence of late-stage
colorectal cancer for individuals who received a flexible sigmoidoscopy compared to
those who did not (RR 0.75 [95% CI 0.66-0.86]); the NNS was 577.23
Possible complications of flexible sigmoidoscopy include bleeding, perforation of the
rectum or large intestine, and the risk of having an adverse reaction to sedatives.23,42
Studies have noted that barriers to undergoing flexible sigmoidoscopy include the fear of
being awake during the procedure, the dissatisfaction with only examining the distal
colon, the invasiveness of the procedure, and the burden of achieving satisfactory bowel
preparation.40,43

2.3.3 Colonoscopy
Colonoscopy is a form of lower bowel endoscopy that is used to directly visualize the
anus, rectum, sigmoid colon, descending colon, transverse colon, ascending colon,
cecum, and terminal ileum.23,44 Performed by either a gastroenterologist or a general
surgeon, the procedure typically involves sedating a patient, followed by inserting a
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several-foot-long endoscope through the anus, and through the lumen of the rectum and
large bowel. Endoscopists may also elect to inspect the terminal ileum in selected cases,
namely in Crohn’s disease, microscopic colitis, chronic diarrhea, and lower
gastrointestinal bleeding. For experienced endoscopists, the anus-to-cecum time ranges
from 7 to 20 minutes, and the withdrawal time (an important quality indicator) is
approximately 7 minutes.44
Endoscopists may also perform biopsies of intestinal mucosa for the diagnosis of
colorectal pathologies, and grading of biopsied carcinoma tissue may then be
performed.44 During these biopsy procedures, the endoscopist may also perform a
polypectomy, and may use India ink staining to mark the location of lesions. In case of
lower gastrointestinal bleeding, colonoscopy is an important therapeutic modality that can
be used to achieve hemostasis: submucosal epinephrine injection, clipping, cauterization
and band ligation therapy are possible endoscopic therapeutic options.
Both screening and diagnostic indications exist for colonoscopy.23,44 It may be used for
colorectal cancer screening in eligible asymptomatic individuals, but is also commonly
employed for the diagnostic work-up of symptoms like gastrointestinal bleeding,
constipation, diarrhea, unexplained fatigue, all of which could be symptoms of serious
underlying gastrointestinal pathology. It is important to emphasize that screening
colonoscopies require adequate bowel cleansing, with the use of hyperosmotic agents
such as polyethylene glycol to adequately visualize the intestinal mucosa.45
Although colonoscopy has the potential to provide clinical benefit, its exact efficacy in
relation to FOBT and flexible sigmoidoscopy has not yet been determined through RCTs.
This is particularly important considering that wait times for colonoscopy have increased
over time, and considering the high resource burden of performing colonoscopies in
terms of personnel (gastroenterologists, nurses, anesthesiologists, general surgeons),
endoscopy suite availability, equipment and maintenance costs.2,46 Indeed, the lack of
RCT evidence was a critical factor in the CTFPHC’s recommendation that colonoscopy
should not be used as a primary screening test for colorectal cancer.2
Due to the lack of RCTs comparing colonoscopy to FOBT or flexible sigmoidoscopy, the
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next best study designs to evaluate colonoscopy efficacy are the prospective cohort study
and meta-analyses of observational studies. A prospective cohort study that helped form
the basis of the USPSTF recommendation that colonoscopy can be used as a first-line
screening test followed 88,902 women over a period of 22 years.47 This long follow-up
time is important, given that it takes an average lag time of 10 years for a precursor lesion
to transform into cancer. A significant decrease in colorectal cancer mortality was
observed in people who underwent colonoscopy compared to people who did not (HR,
0.32 [95% CI, 0.24 to 0.44]). As with all cohort studies, there may have been unmeasured
confounders present, including income, education level, and use of over-the counter
medications (such as aspirin), hormone therapy, unknown family history of colorectal
cancer or hereditary polyposis syndromes.48 The USPSTF judged that it remains unclear
whether the mortality benefit resulted from a single colonoscopy, or from multiple
colonoscopies, or from screening and surveillance colonoscopies.49 It is also unclear as to
how frequently people should be undergoing colonoscopy in order to attain a benefit.
A meta-analysis assessing colonoscopy versus no screening involved 19 studies and
included a total of 2,858,087 participants. Colonoscopy resulted in a 61% reduction in
colorectal cancer mortality (RR 0.39; 95% CI, 0.31-0.50) and resulted in a greater
mortality benefit than FOBT and flexible sigmoidoscopy.50 The sensitivity and specificity
of colonoscopy for detecting adenomas approaches 100%.51
Colonoscopy carries a greater degree of risk than flexible sigmoidoscopy. The risk of
intestinal perforation is 0.061% (vs 0.001% for flexible sigmoidoscopy), minor bleeding
(0.27% vs 0.05%), major bleeding (0.11% vs 0.009%), and death (0.035% vs 0.015%).23
However, the risk of colonoscopy may be lower when performed for screening
indications in average-risk individuals, since there may be a greater risk of intestinal
perforation in people with intestinal diseases, such as in Crohn’s disease and ulcerative
colitis.52

2.3.4 Other colorectal cancer screening modalities
Computed tomography (CT) colonography is a technology that some patients may elect
to undergo after consultation with their physician. Benefits of CT colonography include:
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non-invasiveness, avoidance of sedation, and no driving restrictions after the procedure.23
Its efficacy has not been fully characterized, and the risks of extra-colonic CT findings
(i.e. overdiagnosis) are not yet completely understood, as it is a relatively new screening
technology and is not widely available.49 However, quinquennial CT colonography is
currently recommended by the USPSTF.49
No clear mortality benefit was found in one systematic review for barium enemas, digital
rectal examinations, serologic tests, or fecal DNA testing or other tests.23

2.4 Canadian Task Force on Preventive Health Care
recommendations
The CTFPHC is an independent group of physicians and scientists who develop various
preventive health guidelines. The task force indicates the quality of evidence (high,
medium, low) that informs their recommendations, based on factors such as
randomization procedure, limitations, and the size of the confidence interval of studies
identified in systematic reviews.
The CTFPHC indicates the strength of each of its recommendations (strong vs weak).
The strength of the recommendation is based on weighing the benefits vs harms, the
range of values and preferences of patients, and the resource requirements of the
recommendation.
The 2001 CTFPHC colorectal cancer screening guidelines are applicable for people who
are at average-risk of colorectal cancer, and the Task Force made the following
recommendations: 1) There is good evidence to screen asymptomatic individuals age 50
or older with annual or biennial FOBTs.5 2) There is fair evidence to screen
asymptomatic individuals age 50 or older with flexible sigmoidoscopy in the periodic
health examination. There was no specific suggested screening frequency for flexible
sigmoidoscopy.5
In 2016, the CTFPHC updated their recommendations based on changes in screening
technology and practice since 2001: 1) adults aged 50 to 59 should be screened with
FOBT every two years or with flexible sigmoidoscopy every 10 years (weak

13
recommendation, moderate-quality evidence); 2) adults aged 60 to 74 should be screened
with FOBT every two years or with flexible sigmoidoscopy every 10 years (strong
recommendation; moderate-quality evidence); 3) adults aged 75 and older should not be
screened for colorectal cancer (weak recommendation; low-quality evidence); 4)
colonoscopy should not be used as a screening test for colorectal cancer (weak
recommendation; low-quality evidence).2 These recommendations only apply to
individuals who are at average-risk for colorectal cancer i.e. not applicable for people
with a prior diagnosis of colorectal cancer or polyps, Crohn’s disease or ulcerative colitis,
signs or symptoms of colorectal cancer, or a family history of colorectal cancer in one or
more first-degree relatives.
Despite the lack of randomized trial evidence, the USPSTF recommended screening for
adults 50 to 70 years of age with FOBT, sigmoidoscopy, or colonoscopy, which may in
part reflect them putting a lower value on the lack of direct RCT evidence for
colonoscopy, and on the potential for the benefits of colonoscopy to outweigh its harms.49
This is in contrast to the CTFPHC guidelines, which places a higher value on the lack of
RCT evidence for colonoscopy, and thus did not recommend colonoscopy as a first-line
screening test. Additionally, Cancer Care Ontario indicated that colonoscopy may be used
for the screening of people at increased risk of colorectal cancer, and for people who are
unaware of whether they have a family history of colorectal cancer.6 However, it is
important to note that the CTFPHC made a weak recommendation regarding
colonoscopy, meaning that patient values and preferences must be emphasized during the
screening decision-making process.

2.5 Colorectal cancer screening in Ontario
Prior to April 2008, colorectal cancer screening in Ontario was opportunistic (since there
was no organized, provincial screening program), and the responsibility for patient
education and implementation of screening was primarily held by family physicians, who
would recommend screening during patient visits, along with specialist support for
colonoscopy screening and follow-up when necessary. Since April 2008, Ontario’s Colon
Cancer Check program has provided population-based, organized colorectal cancer
screening for eligible Ontarians.22 The launch of Colon Cancer Check was done in
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conjunction with an intense public media campaign, pay-for-performance incentives for
physicians, as well as physician-specific education regarding the Colon Cancer Check
program and evidence supporting the use of primary FOBT for population-based
screening.17,22 People can access the Colon Cancer Check program through their primary
care physician, as it is a provider-led program. For individuals who are not rostered to a
family medicine practice, FOBT kits can be obtained from community laboratories in
Ontario, and the Colon Cancer Check program will link these unrostered individuals to a
family physician for test interpretation and follow-up.22 To be eligible for participation in
Colon Cancer Check’s average-risk screening program, individuals must be ages 50 to
74, not have a first-degree relative diagnosed with colorectal cancer, and not have a
history of colorectal polyps or inflammatory bowel disease.22 The Colon Cancer Check
recommends biennial FOBT, and flexible sigmoidoscopy every 10 years, but there was
not sufficient evidence in the literature to recommend colonoscopy as a first-line
screening test (apart from people who do not know whether they are at increased risk by
virtue of having a family history, or in people with established risk factors for colorectal
cancer). Despite not recommending colonoscopy for average-risk screening, it has been
estimated that there are at least 67,000 colonoscopies performed in Ontario each year.53
As of 2003, approximately 15% of eligible Ontarians were compliant with biennial
FOBT, and that number has increased to approximately 30% as of 2012.22,54 Despite this
increasing trend in FOBT participation, uptake has remained markedly lower than the
provincial minimum target of 36%,22 and the rate of increase in participation plateaued
following the introduction of the Colon Cancer Check program.18 Additionally, in
composite analyses performed in the year 2014 of FOBT, flexible sigmoidoscopy and
colonoscopy, approximately 40% of average-risk Ontarians (1.6 million people) were
overdue for colorectal cancer screening.55
Factors associated with decreased colorectal cancer screening compliance among screeneligible people in the general Ontario population include: an age of 50 to 54 (versus 70 to
74), living in rural or very remote regions (versus urban regions), and residing in a
neighborhood with a lower income quintile (versus higher neighborhood income
quintile).22
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2.6 Physician attitudes, beliefs and preferences regarding
colorectal cancer screening
Existing studies provide valuable insight into physicians’ beliefs and preferences about
colorectal cancer screening. However, most of these studies are cross-sectional surveys,
consisting of self-reported data that are subject to recall and social desirability biases.
Most of these studies also do not have a comparator group of non-physicians in which to
put the results into context.56,57. Notwithstanding those potential limitations, these studies
suggest that most physicians (76%) support colorectal cancer screening and believe it is
an important component of preventive health care.58
A recent qualitative study conducted in 2012 surveyed 65 family physicians in Ontario
and found that physicians strongly favored colonoscopy over FOBT for average-risk
individuals.59 Comments from physicians included:
“In my opinion, the fecal occult blood has failed me many times…I continue to
use it…for…completeness…but for the most part I recommend…colonoscopy.”
“With colonoscopies being so easy to perform and so accurate and so safe, I never
had a mishap. I prefer…that route…no false positives and basically no false
negatives.”
“To me, the frustration is some patients who feel it’s [the FOBT kit]…a dirty
thing to do and they don’t want to do it.”
Physicians preferences for screening patients
In Alberta, 70% of 187 specialists who were surveyed indicated that they recommend
colonoscopy for average-risk patients, 47% recommend flexible sigmoidoscopy, and 65%
recommend FOBT (some physicians recommended more than one screening modality).60
Given that 65% of physicians recommended FOBT for their patients, and yet only 16% of
physicians would undergo only FOBT for their own screening,60 some physicians may
believe that FOBT is acceptable for the general population, but not for themselves.
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Further, in a survey of 965 Albertan family doctors conducted in 2002, only 9.4% of
respondents thought that FOBT was an excellent or very good screening test, and 19.2%
rated it as a poor test.61 Additionally, 88.2% of physicians reported that the sensitivity and
specificity of FOBT is an important barrier that prevents them from recommending
FOBT to their patients.
In a survey of 563 family doctors and specialists in Calgary, only 58% of physicians
recommend colorectal cancer screening (with any screening modality) for age-eligible
patients who present to the clinic without a family history of colorectal cancer.62
Physicians preferences for their own screening
A survey of 187 specialist physicians in Alberta, 70% of whom indicated that they would
never undergo any colorectal cancer screening other than colonoscopy.60
Aligning with other studies,14,60 64.1% of 965 surveyed Albertan family doctors indicated
that they prefer colonoscopy for their own screening.61
A lack of physician support for FOBT and their personal preference for invasive highly
sensitive tests has also been observed in Ontario. A cross-sectional survey of 465 family
doctors in Ontario showed that 50.8% of respondents preferred colonoscopy once every
10 years for their own colorectal cancer screening, while 39.6% preferred biennial FOBT,
and 0.4% preferred flexible sigmoidoscopy once every five years.14 In addition, 54.4% of
physicians believed that colonoscopy was associated with the greatest decrease in
mortality relative to all other colorectal cancer screening modalities. This study also
found that when physicians believe FOBT to be highly sensitive, they are more likely to
prefer FOBT versus colonoscopy for their own screening.
A study of 1,121 Canadian specialist physicians showed that among physicians who did
not receive colorectal cancer screening, 14% of them believed that there was not enough
data to warrant colorectal cancer screening using any screening modality. However, the
most commonly cited barrier to screening (49%) was lack of time.15

2.7 Factors associated with cancer screening
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2.7.1 Age
Older age is a recognized correlate of higher colorectal cancer screening uptake in both
physicians and non-physicians. One cross-sectional survey of Canadian specialist
physicians showed that the proportion of physicians who received FOBTs increased from
25% for doctors aged 50 to 64, to 30% for those aged 65 or older.15 These findings were
corroborated in a study of 138 family physicians in southern Israel who exhibited more
than a 4-fold increase in FOBT screening for physicians over age 50, compared to those
younger than 50.65 These findings are also consistent with population-based data from
Ontario indicating that older individuals are more likely to be compliant with FOBT
recommendations compared to younger individuals.16

2.7.2 Sex
Numerous studies have shown that females are more likely than males to participate in
colorectal cancer screening, both among physicians and the general public. Qualitative
research suggests that men appear to be less knowledgeable about colorectal cancer
screening than women.40 As well, men commonly cite that a key barrier to undergoing
lower bowel endoscopy is the threat that procedure poses to their sense of masculinity.66
However, this psychosexual barrier would not necessarily apply to FOBT, and unlike
males in the general population, we do not expect male physicians to have low
knowledge about colorectal cancer screening.
One cross-sectional survey of Canadian physicians showed that 37% of females chose
FOBT as a first-line screening test, compared to only 26% of males.15 This difference in
colorectal cancer screening compliance appeared to be less pronounced in the general
Ontario population, as one study showed that in 2011, 42.9% of screen-eligible females
were up-to-date with colorectal cancer screening, compared to 39.5% of males.18 More
recent data from 2014 show that a greater proportion of screen-eligible men in Ontario
were overdue for colorectal cancer screening compared to women (43% vs 37%,
respectively).16
In one study, patients of female physicians were 1.37 times more likely to participate in
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colorectal cancer screening compared to patients of male physicians.67

2.7.3 Income level
It has been demonstrated that higher-income individuals are more likely to be compliant
with cancer screening compared to lower-income individuals. In Ontario, from 2005 to
2011, screening in the general population increased in each income quintile, but the
difference in colorectal cancer screening in the highest versus lowest income quintiles
also increased.18 In 2011, approximately 10% more screen-eligible Ontarians in the
highest income quintile underwent colorectal cancer screening compared to people in the
lowest income quintile.18
The potential association between income and cancer screening compliance in physicians
has not been thoroughly examined, presumably in part due to a lack of access to
information regarding physician compensation in most jurisdictions, as well as an
assumption that most physicians have a high after-tax income. However, this assumption
is likely not uniformly true, particularly among salaried residents and fellows, and among
physicians who work part-time.

2.7.4 Residential status
Residential status provides information regarding geographic disparities in access to
cancer screening. This is particularly important given that Ontario has a large
geographical area. To operationalize residential status, studies from Ontario generally
dichotomize geographic location into rural (less than 10,000 people in a given
municipality) versus urban,68 and some studies use the rurality index measure which
accounts for the distance to healthcare facilities.69
Analyses from Ontario show that a higher proportion of screened individuals live in
urban, compared to rural or remote regions, although in some analyses this difference is
marginal.16 One study showed that among average-risk Ontarians aged 50-74, screening
participation was similar in people living in rural versus residential areas for FOBT
(14.7% versus 15%, respectively), and for the composite of two-year FOBT participation,
or five-year large bowel endoscopy (flexible sigmoidoscopy or colonoscopy)
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participation (rural 40.2% versus 41.7%, respectively).18 These results suggest that there
may not be a clear geographic disparity among the general Ontario population with
respect to accessing FOBT or large bowel endoscopy. Studies examining the potential
association between screening and residential status in physicians are lacking.

2.7.5 Foreign medical graduate status
Physicians who have trained and practiced in foreign countries have exposure to health
care systems that may use cancer screening protocols that differ from CTFPHC
guidelines, and this may influence their own cancer screening behaviors, and how they
counsel patients.70,71 In some regions of the world, a lack of health care infrastructure and
inadequate financial resources are important barriers that may contribute to low screening
in the general population, as well as minimal physician experience using modern
screening technologies.70,72
Although prior work has shown that physicians practicing in Canada who graduated from
medical school in the Middle East or South Asia are much less likely to screen their
patients for colorectal cancer relative to Canadian medical school graduates,67 there is no
single study that clearly addresses the potential association between physicians’ personal
cancer screening behaviors and their country of medical school graduation.

2.7.6 Physician specialty
Specialty-specific guidelines can influence physicians’ attitudes and practices regarding
cancer screening.12 One study of Canadian specialists demonstrated inter-specialty
variability in cancer screening behaviors: 41% of psychiatrists versus 28% of radiologists
selected FOBT for their colorectal cancer screening.15 In contrast, among
gastroenterologists (who have expert knowledge in colorectal cancer screening, diagnosis
and treatment) only 5% chose to undergo FOBT, while 91% of them preferred highersensitivity screening methods like colonoscopy, despite the increased time requirement
and invasive nature of colonoscopy versus FOBT.
Another study of physicians in the United States suggested that family physicians and
general internal medicine physicians were more likely to recommend colorectal cancer
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screening for their patients than physicians in other specialties, suggesting that there may
be a differential focus on prevention between specialties.73 Additional quantitative and
qualitative studies are needed to fully understand the nature of these inter-specialty
differences.

2.7.7 Accessing general medical care
Accessing physician services more frequently increases one’s opportunity to engage in
preventive health behaviors, including secondary cancer prevention. A study of 12,776
individuals used data from the Canadian Community Health Survey and found that
compared to people who did not access physician services in the year before the survey,
people who had one to two physician contacts in the year preceding the survey were
significantly more likely to undergo colorectal cancer screening (OR 1.97 [95% CI, 1.56–
2.48]).74 Having regular primary care physician visits are especially important in the case
of provider-led screening programs such as the Ontario Cervical Screening Program,
since the only way to receive Pap testing is directly from a physician, whereas FOBTs
may be obtained from community pharmacies across Ontario.

2.8 The influence of physicians’ screening behavior on
screening uptake in their patients
It has been shown that patients are more likely to undergo screening if their physician
undergoes screening themselves. This includes not only colorectal cancer screening; it
extends to mammography, pneuomococcal and influenza vaccination, and hypertension
screening.19 For instance, in a cross-sectional study of 1,488 primary care physicians in
Israel and their 1,886,791 patients, analysis of administrative data showed that 50% of
patients underwent colorectal cancer screening if their physician underwent colorectal
cancer screening, versus 45.6% for patients of unscreened physicians.19
It has even been suggested that patients of female physicians are more likely to undergo
colorectal, breast, and cervical screening compared to patients of male physicians.19,67
Additionally, patients of Canadian medical school graduates are more likely to undergo
colorectal cancer screening compared to patients of non-Canadian medical school
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graduates.67
This small but important body of research underscores a fundamental principle:
physicians who take care of their own health may have more credibility when advising
patients if they disclose their screening status to their patients, and may develop better
patient relationships, which can result in more active patient participation in cancer
screening. When physicians lead from the front in preventive health care, not only does it
improve their own health; their patients benefit too.

2.9 Conclusion
The burden of colorectal cancer is substantial, and yet despite physicians’ self-reported
support for cancer screening, population-level cancer screening participation remains
suboptimal, given that 39% of eligible Ontarians were overdue for screening as of 2015.
Furthermore, surveys of physicians’ personal cancer screening behaviors show variable
results, and are subject to recall and social desirability biases. There is also evidence that
factors such as older age, female sex, higher income quintile, urban residential status,
graduation from a Canadian medical school, and higher frequency of physician visits may
be associated with a higher rate of cancer screening behaviors. Medical specialty may
also influence cancer screening rates (varies by specialty and by screening test, as
described above). The aforementioned factors have not been extensively evaluated in
physicians using health administrative databases.
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Chapter 3
3 Rationale and research objectives
3.1 The need for research
There are several important limitations in existing literature on physicians’ colorectal
cancer screening behaviors. To date, there has not been an analysis of North American
physicians’ cancer screening behaviors that leverages health administrative databases.
Prior studies primarily consist of surveys that rely on self-reported information,14,15,20,75
and therefore are subject to recall and social desirability biases. Many of these studies
have small sample sizes, focussed on limited geographic areas, or did not specifically
evaluate screening among average-risk physicians. Additionally, these studies have
shown variable physician support for different screening modalities. Given that
physicians are uniquely positioned to positively influence colorectal cancer screening in
their patients, the aforementioned limitations and findings of prior studies warrants an
examination of physicians’ uptake of colorectal tests using health administrative
databases. It is also interesting to note that physician support for other screening tests,
like Pap smears for cervical cancer and mammography for breast cancer, is more
uniformly high compared to support for different colorectal cancer screening modalities.
This further strengthens our rationale for studying colorectal cancer screening among
physicians.

3.2 Research questions and hypotheses
3.2.1 Primary research question
What is the uptake of colorectal tests (FOBT, flexible sigmoidoscopy, colonoscopy) in
physicians compared to matched non-physicians in Ontario?

Hypothesis: Uptake of colorectal tests will be greater in physicians compared with nonphysicians, although a substantial proportion of both physicians and non-physicians will
be up-to-date with their testing. Physicians will be less likely to undergo FOBT than nonphysicians, and will be more likely to undergo large bowel endoscopy.
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3.2.2 Secondary research questions
1) Which physician-level factors are associated with colorectal test uptake?

Hypothesis: Physicians with the following characteristics will be more likely to undergo
colorectal testing: older age; females (versus males); specializing in general surgery or
gastroenterology (versus family medicine); graduating from a Canadian medical school
(versus graduating from a non-Canadian medical school); living in an urban residential
area (versus a rural area); being in a higher income quintile (versus a lower income
quintile); and accessing care from a primary care physician in the year before the
observation window (versus not having accessed care from a family doctor in the year
before the observation window).

2) Are screen-eligible patients more likely to undergo colorectal testing if their primary
care physician undergoes testing?

Hypothesis: Patients are more likely to be tested if their primary care physician was also
tested.

To answer these questions, we conducted a population-based study using administrative
healthcare data. We examined uptake of colorectal tests as a proxy for colorectal cancer
screening in physicians and matched non-physicians. We assessed which physician level
factors are associated with colorectal test uptake. We further examined whether patients
were more likely to be tested if their primary care physician was tested.
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Chapter 4
4 Methods
4.1 Study design and setting
We conducted a population-based, cross-sectional study using the anonymized
administrative databases held at the Institute for Clinical Evaluative Sciences (ICES) in
Ontario, Canada. Ontario has the largest population of all provinces and territories, with
approximately 13.4 million people as of 2016, 5.4 million of whom were 50 to 74 years
old. Emigration out of Ontario is less than 1% per year.76 Ontario has a universal, singlepayer healthcare system, which provides coverage for medically necessary physician and
lab services, including screening for colorectal, breast and cervical cancer.
The study was done according to an established protocol approved by the Health Science
Research Ethics Board at The University of Western Ontario (London, Canada)
(Appendix A). Participant informed consent was not required since ICES is a prescribed
entity for the purposes of section 45 of Ontario’s Personal Health Information Privacy
Act. This research described in this thesis was conducted and reported according to
REporting of studies Conducted using Observational Routinely-collected health Data
(RECORD) guidelines (Appendix B).77

4.2 Timeframe
Exposure status (physician vs. non-physician) and outcomes were ascertained on the
index date of April 21, 2016, as we had information on physicians’ CPSO registration
status as of this date. In accordance with CTFPHC and Cancer Care Ontario
recommendations, as well as other analyses of cancer screening in Canada,2,5,18,35 the
observation windows during which outcomes were evaluated extended up to two years
before the index date for FOBT, five years before the index date for flexible
sigmoidoscopy, and ten years before the index date for colonoscopy. Baseline
characteristics and healthcare utilization for physicians and non-physicians were
evaluated within the five years before the index date (see Table 2a and Table 2b for
details).
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4.3 Data sources
Administrative databases allow for the investigation of clinical questions using
population-based data.78 This study used six data holdings at ICES to evaluate baseline
characteristics, exclusion criteria, covariates and colorectal test uptake. These databases
were linked using unique encoded identifiers (ICES Key Numbers) at ICES.
The Registered Persons Database (RPDB) contains demographic and vital status data for
every Ontario resident who has ever been issued a health card number, not including
refugee claimants and certain classes of non-immigrants. The RPDB is updated
bimonthly after ICES receives information from Ontario’s Ministry of Health and Long
Term Care. We used the RPDB to ascertain age, sex, postal code, and vital status
information, and the date of last contact with Ontario’s health care system. Postal codes
are linkable to other geographic data such as dissemination area, which can be linked to
census-derived, neighborhood-level data. The dissemination area is the smallest
geographic area (approximately 400 to 700 people) for which census data relevant to our
study were made available. ICES has dissemination area-level information on residential
status and neighborhood income quintile. Quintiles are created for each census
metropolitan area, census agglomeration, or residual area before being aggregated to the
provincial level. The exact financial values of each quintile varies between dissemination
areas, and those values are not made available during the analytic process.
Average after-tax incomes were used to rank dissemination areas within each census
metropolitan area, census agglomeration and provincial residual area, and the distribution
of these neighborhood incomes was used to create income quintiles.79 The Postal Code
Conversion File was used to assign individuals to neighborhood income quintiles by
linking census postal codes to dissemination areas.79
Rural or urban residence was also assigned using the Postal Code Conversion File, and
was based on whether people lived in towns and municipalities outside the commuting
zones of large urban centers (i.e. outside the commuting zone of centres with a population
of 10,000 or more).80
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We used the Ontario Cancer Registry to ascertain prior cancer diagnoses. The Ontario
Cancer Registry contains information on all Ontario residents who received a cancer
diagnosis since 1964, and it captures over 95% of cancer diagnoses in the province, but
does not include non-melanoma skin cancers. Approximately 400,000 records containing
patient demographic, cancer diagnosis and mortality information are added to the Ontario
Cancer Registry annually, and this data comes from: hospital discharge and day surgery
summaries that include a diagnosis of cancer; pathology reports with any mention of
cancer; records of patients referred to one of Cancer Care Ontario’s eight regional cancer
centres in Ontario; and death certificates that list cancer as the underlying cause of death.
The CIHI-DAD contains summarized hospital discharge information for patient-level
demographic (age, sex, postal code) administrative (dates and length of stay, institution
number) and clinical data (diagnoses, procedures) for all individuals hospitalized in
Ontario since 1988, including up to 25 unique diagnosis codes per hospitalization (post2002). This includes people who were discharged, died, transferred, or signed out of
acute, chronic, rehabilitation, and day surgery institutions in Ontario, and does not
include inpatient care in designated psychiatry beds. The diagnosis codes are from the
International Classification of Diseases, 9th revision (ICD-9, and the Canadian
Classification of Diagnostic, Therapeutic, and Surgical Procedures-CCP; pre-April 2002)
and the 10th revision (ICD-10, and the Classification of Health Interventions-CCI; postApril 2002). CIHI-DAD codes were used to assess baseline characteristics and were used
for cohort construction.
The ICES Physician Database comprises information on physician demographics in
Ontario, and was used to ascertain information on country of medical school graduation,
year of medical school graduation, field of specialization. The IPDB incorporates
information provided by the Ontario Physician Human Resource Data Centre (which
conducts annual telephone surveys of Ontario’s physicians), the Corporate Provider
database, and the Ontario Health Insurance Plan (OHIP) database of physician billings.
The OHIP database includes claims for inpatient, outpatient and long-term care physician
and laboratory services that were billed in Ontario since 1991. OHIP records identify the
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physician, patient, diagnosis responsible for the claim, services provided, and the date of
the service. We evaluated OHIP fee codes to evaluate colorectal test uptake and other
procedures, as well as OHIP diagnostic codes to evaluate exclusion criteria and baseline
comorbidities.
The National Ambulatory Care Reporting System contains data on patient visits to
emergency departments. Each record contains patient identifiers, the date of the visit, and
clinical information.
Additionally, ICES entered into a Data Sharing Agreement with the CPSO, enabling the
transfer of a dataset from the CPSO to ICES, providing us with a list of publicly available
information on physicians who were active members of the CPSO as of April 21, 2016.
The three data elements included in this dataset were physicians’ first name, last name
and CPSO number.
Given that some administrative databases held at ICES were not originally designed for
research applications, their data must be analyzed cautiously, and the research question
must be specified accordingly. In order to ensure results from database studies are sound,
it has been recommended that robust descriptions of data tables are provided, that
diagnostic/procedural codes used are validated whenever possible, and that differentiation
is made between clinical versus statistical significance.78

4.4 Study population
We established a cohort of physicians and non-physicians who were residing in Ontario,
Canada as of April 21, 2016. People were classified as physicians if they were active
members of the CPSO on the index date, as this was the most recent date of active
membership for the physicians (the linkage procedure is described in Section 4.5). This
list of active members includes physicians with independent and restricted licenses, as
well as residents/fellows who have a post-graduate education license. Everyone else
residing in Ontario who was not an active member of the CPSO on April 21, 2016 was
classified as a non-physician.

28
Before matching, we excluded people whose RPDB record had missing or invalid
personal identifiers, individuals who died on or before the study entry date, and people
who were not a resident in Ontario, which was defined as the absence of a health care
record in the databases between 2009 and 2016 (a definition consistent with prior ICES
studies).18 We then restricted the cohort of physicians and non-physicians to people ages
52 to 74 as of the index date, to ensure that individuals had at least two years in the ageeligible observation window, in accordance with guidelines.2,5,81 In order to approximate
an average-risk cohort, and to align with guidelines and prior studies,2,5,18,35,67,81 we
excluded individuals with a prior diagnosis of invasive colorectal cancer or anal cancer,
inflammatory bowel disease, large bowel/rectal resections, or colectomy (Figure 1a).
These individuals are more likely to be undergoing FOBT, flexible sigmoidoscopy and
colonoscopy for surveillance of ongoing disease, and/or for the investigation of
gastrointestinal symptoms, which falls outside the purview of average-risk colorectal
cancer screening.

4.5 Linkage procedure
Datasets were linked at ICES using unique, anonymized identifiers. Physicians’ first and
last names, CPSO number, and registration status are publicly available on the CPSO
website, however, a complete list of physicians is not easily obtainable. Therefore, the
CPSO provided to ICES a list of first and last names of all active members as of April 21,
2016, as well as their CPSO number. Physicians were linked probabilistically to RPDB
using their first and last names, enabling linkage to other ICES data holdings using ICES
Key Numbers. Of the 37,125 physicians on the CPSO list, 29,802 (80.3%) were linked to
records in the ICES databases. Then the CPSO number was linked to IPDB to obtain
certain physician-specific characteristics.

4.6 Matching
We greedy matched physicians to non-physicians without replacement using a 1:4 ratio
on the basis of age as of April 21, 2016 (+ 2 years), sex, and Forward Sortation Area
(first three digits of postal codes-average population size 8,000) which accounts for both
socioeconomic status and region of residence. These factors have been used to match
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physicians and non-physicians studies of cancer screening.82 Using SAS, two types of
matching methods were considered for this analysis, greedy matching and optimal
matching. In greedy matching, a set of cases is matched to a set of controls, and once a
match is made, the match is not reconsidered, and the match is the closest match
available. Conversely, in optimal matching, previous matches are considered before
making each match. Greedy matching was chosen since it is more efficient to run
compared with optimal matching, and optimal matching does not perform better in terms
of balancing characteristics between groups.83

Unmatched individuals were excluded from the primary analysis. A matching ratio of 1:4
was used in order to optimize statistical power; ratios greater than 1:4 do not result in
further increases in statistical power.84 Each non-physician served as a control for no
more than one physician, and a unique identification value was assigned to each matched
group.

4.7 Selection of primary care physicians and their patients
To determine which non-physicians were patients of primary care physicians, OHIP
claims from all primary care physicians in the unmatched cohort were reviewed in the
three-year period before April 21, 2016 (Figure 1b). The primary care physician who
submitted the most claims for a particular non-physician (i.e. patient) was defined as that
patient’s primary care physician. This facilitated an additional analysis where we
determined whether physicians’ uptake of colorectal tests was associated with test uptake
in their patients. Primary care physicians were selected for this analysis since they have
primary responsibility for the front-line implementation of the Colon Cancer Check
program.

4.8 Outcomes
The primary outcome of colorectal test uptake was defined as a binary variable at the
individual level in physicians and non-physicians. In accordance with the 2001 CTFPHC
recommendations that were in effect during the study period,5 and for consistency with
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prior reports from Cancer Care Ontario and other studies,18,35 test uptake was assessed by
looking for a record of any of the following as of April 21, 2016: i) FOBT in the past two
years, ii) flexible sigmoidoscopy in the past five years, or iii) colonoscopy in the past 10
years. FOBT, flexible sigmoidoscopy and colonoscopy were evaluated as a composite
outcome, and individually.
Colorectal test uptake was evaluated using OHIP claims codes (Appendix C).
Approximately 95% of physicians in Ontario submit claims to OHIP within the fee-forservice system. An algorithm of claims codes was used to evaluate colorectal test
uptake.85 The sensitivity and positive predictive value of procedure claims codes, such as
those used for colonoscopy, have been demonstrated to be high (up to 98.6% sensitivity
and 96.5% specificity for colonoscopy).86 Although not every code used in our algorithm
has been formally validated, they are all expected to have high sensitivity and specificity,
similar to other fee-for-service codes.87 The codes were also selected based on the clinical
expertise of cancer screening experts, and an understanding of colorectal cancer
screening billing practices. Furthermore, although there is some variation in the literature
regarding algorithms used to define colorectal test uptake,18,35,88 we used a more
comprehensive algorithm compared to some prior analyses in order to achieve higher
sensitivity.
People who are not rostered to a family medicine practice may receive FOBT kits at
community pharmacies, and in order to capture this we also assessed laboratorysubmitted claims codes. It is likely that many primary care physicians have FOBT kits in
their office stock, which they could potentially access for personal use. However, clinical
expertise and discussions with primary care physicians and specialists suggests that most
would still submit the test for analysis and interpretation (captured in our algorithm), and
a positive FOBT would likely lead to an endoscopy procedure (also captured in our
algorithm).

4.9 Statistical analyses
After matching, we assessed the distribution of baseline characteristics (see Table 2a and
Table 2b for details) between physicians and non-physicians using standardized
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differences, since this metric is less sensitive to a large sample size than traditional
hypothesis tests.89 Standardized differences describe differences between group means
relative to the pooled standard deviation (values greater than 10% represent a meaningful
difference between physicians and non-physicians). We expressed continuous variables
as medians and interquartile ranges due to the potential for skewed distributions and
categorical variables as proportions.
Prevalence ratios and prevalence differences were used to compare uptake of colorectal
tests between physicians and non-physicians. Modified Poisson regression was used to
calculate prevalence ratios and their 95% confidence intervals, which was favored over
logistic regression because odds ratios tend to overstate the prevalence ratio in crosssectional studies.90 Prevalence differences and their 95% confidence intervals were
calculated using binomial regression models with an identity link function. Generalized
estimating equations were used to account for the correlation structure within matched
sets.
An interaction term was used to evaluate potential differences in prevalence ratios by sex,
and by age group (52-59, 60-69, 70-74 years), since existing literature demonstrates that
testing is more likely in older age categories, and in women versus men.18
Multivariable regression models were adjusted for the following pre-specified covariates,
measured as of April 21, 2016, and chosen based on consultation with cancer screening
experts and/or because in previous studies they were shown to be correlates of colorectal
test uptake: age (52-59, 60-69, 70-74), sex, urban vs. rural residential status (rural defined
as a population <10,000), neighborhood-income quintile, physician specialty (13
categories), country of medical school graduation (Canadian vs. elsewhere), and the
number of primary care physician visits in the five years before the index date (0, 1-2, 34, >5).18,35,74
The association between uptake of colorectal tests in primary care physicians and their
patients was examined using a modified Poisson regression model, using generalized
estimating equations to account for the correlation structure within primary care
physicians. Models were adjusted for the following patient-level variables: age, sex,
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rurality, neighborhood-income quintile, and the number of primary care visits in the five
years before the index date.
For all analyses we interpreted two-tailed p-values less than 0.05 as statistically
significant. All statistical analyses were conducted using SAS version 9.3 (SAS Institute,
Cary, North Carolina).

4.10 Missing data
Data were near-complete for all variables in this study. Due to the small amount of
missing data, and in the absence of any reason to suspect that the data were missing
systematically, single imputation was used. Variables were imputed as the mode value
when missing. Residential status was imputed as urban for <0.5% of physicians and nonphysicians. Country of medical school graduation was imputed as Canada for 1% of
physicians. Physician specialty was imputed as primary care physician for 1% of
physicians. Information on all other variables was complete.
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Chapter 5
5 Results
5.1 Baseline characteristics
After the exclusions were applied (Figure 1a and Figure 1b), 11,447 physicians and 3,524,725 non-physicians remained in the
cohort. After matching, we retained 11,434 physicians and 45,736 non-physicians. The distribution of baseline characteristics between
physicians and non-physicians was relatively consistent after matching. The median age of physicians on the index date was identical
in non-physicians 60 years (interquartile range [IQR] 56 to 65). A large proportion of the physicians and non-physicians were male
(70.5%). The greatest proportion of physicians and non-physicians were in the highest income quintile (61%), and most resided in
urban areas (~93%). Also, 70.2% of physicians graduated from Canadian medical schools, and 46.3% were primary care doctors.
Physicians had significantly fewer comorbidities than non-physicians. In the five years before the index date, physicians were more
likely to have no visits to a primary care doctor than non-physicians (19.8% vs. 6.5%), and were more likely to have no visits to an
emergency department (72.0% vs. 63.0%). The number of hospital admissions was similar between physicians and non-physicians.
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Figure 1a: Sample flow.
* The

sample of 12,204 physicians (drawn from 29,802 physicians registered with the College of Physicians and Surgeons of Ontario as of April 21, 2016 and successfully linked
to databases at the Institute for Clinical Evaluative Sciences) includes those aged 52–74 years as of April 21, 2016 with valid identifiers (i.e. a valid patient identifier, date of birth,
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sex, medical school graduation date, and at least one health care encounter between 2009 and 2016 [residents do not need to inform Ontario’s Ministry of Health and Long-Term
Care upon emigrating from the province, and this criterion is used a proxy to exclude those who have emigrated]).
† The sample of 3,797,566 non-physicians (drawn from the Ontario Registered Persons Database) includes all residents of Ontario aged 52–74 years as of April 21, 2016 with
valid identifiers (i.e. a valid patient identifier, valid data on date of birth and sex, and at least one health care encounter between 2009 and 2016 [residents do not need to inform
Ontario’s Ministry of Health and Long-Term Care upon emigrating from the province, and this criterion is used a proxy to exclude those who have emigrated]).
‡ The age restriction was applied to ensure that all persons in our study had screening tests assessed for at least two years before the study entry date (screening is recommended to
begin at age 50, so individuals who were age 52 on April 21, 2016 would be assessed for screening starting from their 50 th year).
§ These individuals are more likely to be symptomatic and undergoing long-term surveillance for colorectal disease.
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Figure 1b: Cohort build for the analysis of primary care physicians and their patients.
* As

described in Figure 1a, this sample included all residents of Ontario aged 52–74 years as of April 21, 2016 with a valid patient identifier, valid data on date of birth and sex,
and at least one health care encounter between 2009 and 2016 (residents do not need to inform Ontario’s Ministry of Health and Long-Term Care upon emigrating from the
province, and this criterion is used a proxy to exclude those who have emigrated). Physicians were identified by linkage with the College of Physicians and Surgeons of Ontario
(we excluded <5 whose medical school graduation occurred after April 21, 2016). The age restriction was applied to ensure that all persons in our study had screening compliance
assessed for at least two years before the study entry date (screening is recommended to begin at age 50, so individuals who were age 52 on April 21, 2016 would be assessed for
screening from age 50–52).
† From Figure 1a: no evidence of any of the following before April 21, 2016: invasive colorectal lesions or anal cancer, inflammatory bowel disease, or colorectal procedures
(large bowel/rectal resections; colectomy).
‡ To link patients with their primary care physicians, we reviewed all billing claims of primary care physicians during the 3-year period before April 21, 2016; the physician with
the most submitted claims for a particular patient was defined as that patient’s primary care physician.
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Table 2a: Characteristics of matched physicians and non-physicians*,†,‡,§
Physicians
(N = 11 434)

Non-physicians
(N = 45 736)

Age, years
Median (IQR)
60 (56 to 65)
60 (56 to 65)
52–59
5181 (45.3)
20 726 (45.3)
60–69
5084 (44.5)
20 333 (44.5)
70–74
1169 (10.2)
4677 (10.2)
Sex
Men
8056 (70.5)
32 224 (70.5)
Women
3378 (29.5)
13 512 (29.5)
Urban vs rural residence¶
Urban
10 649 (93.2)
42 466 (92.8)
Rural
785 (6.9)
3270 (7.1)
**
Neighborhood income quintile
1 (lowest)
827 (7.2)
3308 (7.2)
2
655 (5.7)
2620 (5.7)
3
1077 (9.4)
4308 (9.4)
4
1904 (16.7)
7616 (16.7)
5 (highest)
6971 (61.0)
27 884 (61.0)
No. visits to a family physician††
Median (IQR)
3 (1 to 7)
9 (4 to 15)
0
2268 (19.8)
2993 (6.5)
1–2
2715 (23.7)
4385 (9.6)
3–4
2143 (18.7)
5053 (11.0)
>5
4308 (37.7)
33 305 (72.8)
No. visits to the emergency department††
Median (IQR)
0 (0 to 1)
0 (0 to 1)
0
8234 (72.0)
28 811 (63.0)
1–2
2692 (23.5)
12 786 (28.0)
>3
370 (3.2)
2669 (5.8)
No. hospital admissions††
Median (IQR)
0 (0 to 0)
0 (0 to 0)
0
10 350 (90.5)
40 872 (89.4)
>1
1084 (9.5)
4864 (10.6)
Comorbidities††
Hypertension
2906 (25.4)
17 323 (37.9)
Liver disease
217 (1.9)
1731 (3.8)
Diabetes
1151 (10.1)
7985 (17.5)
Charlson comorbidity score‡‡
Median (IQR)
0 (0 to 0)
0 (0 to 0)
0
11 085 (96.9)
43 585 (95.3)
>1
349 (3.1)
2151 (4.7)

Standardized
difference
(%)∥
0
0
0
0
0
0
1
1
0
0
0
0
0
.
40
30
18
4
.
19
5
9
.
4
4
27
11
22
.
9
9
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Abbreviations: IQR, Interquartile range (25th–75th percentile).
* All values are reported as No. (%) unless otherwise specified.
† Physicians registered with the College of Physicians and Surgeons of Ontario as of April 21, 2016.
‡ Physicians were matched to non-physicians using a 1:4 ratio based on age, sex and the first three digits of residential
postal code (i.e. Forward Sortation Area [average population size 8000]), which was used to match on neighborhood
characteristics and income.
§ Characteristics as of April 21, 2016 (the index date) unless otherwise specified.
∥ Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure
of the difference between group means relative to the pooled standard deviation. A value greater than 10% is
considered a meaningful difference.
¶ Urban was defined as living in a municipality with a population >10 000; missing data was imputed as urban for
<0.5% of physicians and non-physicians.
** Quintiles of neighborhood income, adjusted for household size. Missing data (<0.5% of physicians and nonphysicians) was imputed with the mode.
†† Assessed in the 5-year period before the index date (April 21, 2016).
‡‡ Calculated using 5 years of hospitalization data preceding the index date. “No hospital admissions” received a score
of 0.
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Table 2b: Additional characteristics in physicians*
No. physicians
(N=11 434)
Years since medical school
graduation
Median (IQR)
35 (30 to 40)
Years since first billing claim
Median (IQR)
29 (24 to 34)
Medical school†
Canadian
8028 (70.2)
Non-Canadian
3406 (29.8)
Specialty‡
Anesthesiology
482 (4.2)
Radiology§
404 (3.5)
Emergency medicine∥
310 (2.7)
Gastroenterology
114 (1.0)
Family medicine
5299 (46.3)
Internal medicine¶
1389 (12.1)
Oncology**
173 (1.5)
Other††
70 (0.6)
Pathology
281 (2.5)
Pediatrics‡‡
542 (4.7)
Psychiatry
1007 (8.8)
General Surgery
238 (2.1)
Other Surgery§§
1138 (9.9)
Abbreviations: IQR, Interquartile range (25th–75th percentile).
* All values are reported as No. (%) unless otherwise specified.
† Missing values for country of medical school graduation were imputed as Canadian for 1% of physicians.
‡ Missing values for specialty were imputed as family physician for 1% of physicians.
§ Included diagnostic radiologists and nuclear medicine specialists.
∥ Included physicians whose specialty was classified in the ICES Physician Database as family physicians/emergency
medicine.
¶ Included general internal medicine and all internal medicine subspecialties, aside from gastroenterology and
oncology, which are presented separately.
** Included medical oncologists, radiation oncologists, and gynecologic oncologists.
†† Included fellows, occupational medicine specialists, and community medicine/public health physicians.
‡‡ Included general pediatrics, all pediatric medical and surgical subspecialties, and neonatal/perinatal medicine.
§§ Included all surgical subspecialties (other than general surgery), including obstetrics and gynecology.
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5.2 Primary analysis
Uptake of colorectal tests (FOBT in the past two years, flexible sigmoidoscopy in the past
five years, or colonoscopy in the past 10 years) was 67.9% (95% CI, 67.0 to 68.7%) in
physicians and 66.6% (95% CI, 66.2 to 67.1%) in non-physicians (prevalence ratio for
physicians, 1.02; 95% CI, 1.00 to 1.03; P=0.01) (Table 3). Physicians were significantly
less likely to undergo FOBT than non-physicians (11.6% vs. 26.2%; prevalence ratio for
physicians, 0.44; 95% CI, 0.42 to 0.47; P<0.001), and more likely to undergo
colonoscopy (60.1% vs. 48.6%; prevalence ratio for physicians, 1.24; 95% CI, 1.22 to
1.26; P<0.001). Uptake of flexible sigmoidoscopy was similar between the two groups.

41
Table 3: Uptake of colorectal tests in matched physicians and non-physicians*,†,‡

Abbreviations: CI, confidence interval; FOBT, fecal occult blood test.
* Physicians were matched to non-physicians using a 1:4 ratio based on age, sex and the first three digits of residential postal code (i.e. Forward Sortation Area [average population
size 8000]), which was used to match on neighborhood characteristics and income.
† Uptake was defined by a record of the following as of April 21, 2016: (i) a fecal occult blood test in the past two years, (ii) flexible sigmoidoscopy in the past five years, or (iii)
colonoscopy in the past 10 years.
‡ Individuals who received multiple tests during the screening period were counted only once for the composite outcome of fecal occult blood test, flexible sigmoidoscopy, or
colonoscopy.
§ Prevalence ratios were derived from modified Poisson regression models using generalized estimating equations to account for the correlation structure within match sets.
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5.3 Secondary analyses
Factors associated with colorectal test uptake in physicians
In multivariable modelling, colorectal test uptake was significantly higher in older
physicians, in physicians residing in urban (vs. rural) areas, in physicians in the highest
income quintile (vs. the middle quintile), in anesthesiologists, radiologists,
gastroenterologists and general surgeons (vs. primary care physicians), in graduates of
Canadian (vs. non-Canadian) medical schools, and in those who visited a primary care
doctor in the five years before the index date (vs. those with no visits) (Table 4).
Table 4: Predictors of colorectal test uptake in physicians (N = 11 434).*, †
Adjusted prevalence
Percentage tested
P
Characteristics
ratio‡
(prevalence) (%)
Value
(95% CI)
Age category
52–59 years
3446 (66)
0.96 (0.92 to 1.00)
.06
60–69 years
3520 (69)
1.00 (0.96 to 1.04)
.94
70–74 years
804 (69)
1.00 [reference]
Sex
Men
5398 (67)
1.01 (0.98 to 1.03)
.60
Women
2372 (70)
1.00 [reference]
Rural vs urban residence
Rural
508 (65)
0.94 (0.89 to 0.99)
.01
§
Urban
7262 (68)
1.00 [reference]
Neighborhood income quintile∥
1 (lowest)
553 (66)
1.04 (0.98 to 1.11)
.22
2
422 (64)
0.99 (0.93 to 1.06)
.82
3
695 (65)
1.00 [reference]
4
1264 (66)
1.03 (0.98 to 1.08)
.30
5 (highest)
4836 (69)
1.07 (1.02 to 1.12)
.003
Specialty
Anesthesiology
364 (76)
1.17 (1.11 to 1.23)
<.001
Radiology
294 (73)
1.09 (1.03 to 1.16)
.01
Emergency
209 (67)
1.01 (0.93 to 1.09)
.80
medicine
Gastroenterology
82 (72)
1.14 (1.02 to 1.28)
.02
Family medicine
3562 (67)
1.00 [reference]
Internal medicine
896 (65)
1.01 (0.97 to 1.05)
.74
Oncology
119 (69)
1.08 (0.98 to 1.19)
.10
Other
49 (70)
1.02 (0.88 to 1.19)
.78
Pathology
191 (68)
1.04 (0.96 to 1.13)
.30
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Characteristics

Pediatrics
Psychiatry
General surgery
Other surgery
Medical school
Canadian
Non–Canadian
No. family physician visits¶
0
1–2
3–4
>5
* Physicians

355 (66)
722 (72)
172 (72)
755 (66)

Adjusted prevalence
ratio‡
(95% CI)
0.99 (0.93 to 1.05)
1.02 (0.98 to 1.07)
1.15 (1.07 to 1.24)
1.03 (0.98 to 1.07)

5722 (70)
2048 (62)

1.17 (1.14 to 1.21)
1.00 [reference]

1059 (47)
1765 (65)
1577 (74)
3369 (78)

1.00 [reference]
1.39 (1.32 to 1.47)
1.59 (1.51 to 1.67)
1.71 (1.63 to 1.79)

Percentage tested
(prevalence) (%)

P
Value
.68
.30
<.001
.27
<.001

<.001
<.001
<.001

registered with the College of Physicians and Surgeons of Ontario as of April 21, 2016.

† Characteristics as of April 21, 2016 (the index date) unless otherwise specified.
‡ A multivariable modified Poisson regression model was used and included all of the above characteristics.
§ Urban was defined as living in a municipality with a population >10 000.
∥ Quintiles of neighborhood income, adjusted for household size.
¶ Assessed in the 5-year period before the index date.

Uptake of colorectal tests in primary care physicians and their patients
Patients were more likely to undergo testing if their primary care physician was tested
(prevalence ratio for physicians, 1.11; 95% CI, 1.09 to 1.12; P<0.001) (Table 5). This
was observed for the composite of FOBT, flexible sigmoidoscopy, or colonocsopy, as
well as for FOBT and colonoscopy individually. Additionally, patients were more likely
to complete a fecal occult blood test if their primary care physician completed this test
(prevalence ratio, 1.27; 95% CI, 1.21 to 1.33), and the same pattern was observed for
colonoscopy (prevalence ratio, 1.24; 95% CI, 1.21 to 1.27).
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Table 5: Uptake of colorectal tests in family physicians and their patients*,†
No.
patients
tested
FOBT, flexible sigmoidoscopy or colonoscopy†
Family physicians (n=4967)

Patients (n=1 701 907)
Proportion
Prevalence ratio (95% CI)
Total no.
Tested (%)
patients
Adjusted‡,§
(prevalence) Unadjusted‡

Yes (n=3337 [67.2%])

779 396

1 134 909

68.7

No (n=1630 [32.8%])

352 397

566 998

62.2

Yes (n=594 [12.0%])

64 748

175 324

36.9

No (n=4373 [88.0%])

445 263

1 526 583

29.2

Yes (n=2896 [58.3%])

493 344

1 000 967

49.3

No (n=2071 [41.7%])

279 162

700 940

39.8

1.11 (1.09 to
1.12)
1.00
[reference]

1.10 (1.08 to
1.12)
1.00
[reference]

1.27 (1.21 to
1.33)
1.00
[reference]

1.27 (1.21 to
1.33)
1.00
[reference]

1.24 (1.21 to
1.27)
1.00
[reference]

1.22 (1.20 to
1.25)
1.00
[reference]

FOBT

Colonoscopy

Abbreviations: CI, confidence interval; FOBT, fecal occult blood test.
* All family physicians and patients met the study’s eligibility criteria (Figure 1b); to identify patients’ family physicians, we reviewed the billing claims of family physicians in
the physician cohort (Figure 1a/1b) during the 3-year period before April 21, 2016; the physician with the most submitted claims for a particular patient was defined as that
patient’s family physician.
† Individuals with a record of any of the following as of April 21, 2016 were considered up-to-date: (i) a fecal occult blood test in the past two years, (ii) flexible sigmoidoscopy in
the past five years, or (iii) colonoscopy in the past 10 years. Individuals who received multiple tests during the screening period were counted only once for the composite outcome
of fecal occult blood testing, flexible sigmoidoscopy, or colonoscopy.
‡ Data were analyzed using a modified Poisson regression model using generalized estimating equations to account for the correlation structure within family physicians.
§ In order to account for potential confounders, we adjusted for several prespecified patient-level variables: age (52–59, 60–69 and 70–74 years), sex, urban residence (urban
[population >10 000] vs rural [population <10 000]), neighborhood-income quintile, and the number of family physician visits (0, 1–2, 3–4, >5 visits) in the 5 years before the
index date (April 21, 2016).
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Subgroup analyses for age and sex
In subgroup analyses, a significant interaction was found for age, but not sex (Appendix
D and Appendix E). In the youngest age group (52-59), uptake of colorectal tests was
higher in physicians than non-physicians (prevalence difference, 4.7%; 95% CI, 3.3 to
6.1%), but in the oldest age group (70 to 74), uptake of colorectal tests was lower in
physicians than non-physicians (prevalence difference, -4.4%; 95% CI, -7.4 to -1.5%);
interaction p-value<0.001.

5.4 Conclusion
Uptake of colorectal tests was 68% in physicians and 67% in non-physicians. Physicians
were less likely to undergo FOBT than non-physicians, and more likely to undergo
colonoscopy. Patients were more likely to undergo colorectal testing if their primary care
physician was tested, and they were more likely to receive the same test as their
physician.
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Chapter 6
6.0 Discussion
6.1 Summary and interpretation of findings
In this population-based study, uptake of colorectal tests was 68% in physicians and 67%
in matched non-physicians. Phrased another way, about one third of physicians and nonphysicians in this screen-eligible cohort were overdue for colorectal cancer screening.
Physicians were more likely than non-physicians to undergo colonoscopy and less likely
to undergo FOBT. Testing in primary care physicians was associated with greater testing
in their patients, and patients were more likely to have the same type of test as their
physician.
Traditionally, physician support for colorectal cancer screening modalities such as FOBT
has been low,14,15,91 and so our finding that physicians were less than half as likely to
undergo FOBT compared to non-physicians was not unexpected. We observed that
11.6% of physicians completed a FOBT. In comparison, previous surveys of Canadian
physicians report that between 27% and 39.6% completed this test,14,15 suggesting that
prior surveys may have overestimated physician support for FOBT, in part due to recall
and social desirability biases, which we avoided due to the use of administrative data.
Prior research indicated that only 20.9% of family doctors in Ontario believe biennial
FOBT is associated with the greatest reduction in colorectal cancer mortality (relative to
other screening modalities), which may be due to their perception that the sensitivity of
FOBT is inadequate.14 This lack of support for FOBT is also reflected in Wilson’s criteria
i.e. support for screening among physicians is not particularly strong when they believe it
has inferior sensitivity, specificity and efficacy, relative to other available screening
modalities.
Physicians were 24% more likely to undergo colonoscopy than non-physicians, and in
absolute terms almost two-thirds of physicians underwent colonoscopy. This is consistent
with prior research showing that physicians prefer colonoscopy for their own screening,
which may be due to its superior sensitivity relative to FOBT.14 Physicians may have
easier access to colonoscopy services than non-physicians in Ontario if they can bypass
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standard referral processes.
Physicians had similar uptake of flexible sigmoidoscopy compared to non-physicians,
and uptake was approximately 59% lower than colonoscopy uptake, and 10% lower than
FOBT uptake. Although flexible sigmoidoscopy reduces mortality from colorectal
cancer,23 it has a lower sensitivity than colonoscopy (40-60% vs 100%, respectively) by
virtue of the fact that it cannot detect lesions proximal to the splenic flexure.41,51 Research
has shown that physicians place a high value on the operating characteristics of screening
tests,14,15 which may explain their preference for colonoscopy over flexible
sigmoidoscopy. Despite low flexible sigmoidoscopy uptake, it is likely a good option for
patients in nurse practitioner-led clinics who wish to undergo endoscopy, but do not want
to experience long wait times associated with colonoscopy. This would be particularly
relevant for individuals living in rural and remote regions where nurse practitioner clinics
are more common.
The average physician income in Ontario is several times the average income for the
general Ontario population.92 In multivariable analyses, we found that higher
neighborhood income physicians were more likely to be tested than lower-income
physicians, although it is difficult to make conclusions as to why this occurred given
physicians’ high incomes. Nevertheless, this trend is consistent with observations from
the general population.35
We also showed that physicians living in rural areas were significantly less likely to be
tested than physicians living in urban areas. This highlights the need to ensure that rural
regions of Ontario are adequately supported with financial and health human resources, to
ensure geographic parity for access to cancer screening services for physicians and their
patients. This finding is in contrast to prior analyses from Ontario that did not show a
difference in screening uptake between people living in rural versus urban areas.16,18
Especially considering the ease of distribution of FOBT kits, residential status should not
be a barrier to colorectal cancer screening for physicians or patients.
We noted significantly greater colorectal test uptake among anesthesiologists,
radiologists, gastroenterologists and general surgeons, relative to family doctors. There is
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very limited data available in the literature on screening preferences of physicians in
different specialties. However, it was unsurprising to find that gastroenterologists and
general surgeons had high test uptake, since they are frequently involved in the screening,
treatment, and long-term follow-up of people diagnosed with colorectal cancer. This
finding is also consistent with a prior study of Canadian doctors’ screening preferences.15
It is unclear as to why the proportion of family doctors tested was not as high as some
other specialists, given that they are responsible for front-line implementation of
colorectal cancer screening in Ontario.
We also found that Canadian graduates were significantly more likely than non-Canadian
graduates to undergo testing. Non-Canadian graduates may have varying levels of
exposure to evidence-based cancer screening throughout their training, and in some
jurisdictions, this may be a function of the high cost of screening technologies.70,72
Diverse cultural practices and religious beliefs may also be important determinants of
colorectal testing in international medical graduates.67 Furthermore, given that patients of
non-Canadian graduates are less likely to undergo cancer screening compared to patients
of Canadian graduates,67 targeted efforts should be made to inform international medical
graduates regarding up-to-date, evidence-based cancer screening recommendations when
they begin practicing in Canada.
As expected, we found that physicians who visited a family doctor at least once in the
five years prior to the index date were significantly more likely to undergo testing
compared to physicians who did not visit a family doctor. A greater number of visits was
associated with greater test uptake, and this is consistent with prior literature.74 More
frequent contact with family doctors increases opportunities for goal-setting in relation to
secondary cancer prevention. Accordingly, all physicians should be encouraged to
maintain regular contact with their own family physicians.
Uptake of colorectal tests in primary care physicians was associated with greater uptake
in their patients. A direct correlation between physicians’ and patients’ preventive health
behaviours has been demonstrated previously, including for vaccination, cancer
screening, exercise, and smoking cessation.19 Since patients were more likely to undergo
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the same type of colorectal test as their physician, this suggests that physicians’ personal
testing preferences and biases are influencing their recommendations to patients. Given
that physicians prefer colonoscopy over FOBT, despite the fact that colonoscopy is more
resource-intensive, has a greater degree of risk, and is not supported by randomized trial
evidence, this may have direct implications for patient care and healthcare system costs.
This also represents an opportunity to increase physician education about evidence-based
colorectal cancer screening, through Cancer Care Ontario materials, continuing medical
education, departmental training sessions and physician health programs.
Cancer prevention should be promoted throughout physicians’ careers, starting from the
time they are junior trainees. Medical schools across North America have taken steps to
address this by integrating personal health and wellness topics into curricula.93 Moreover,
the Canadian medical education framework, CanMEDS, recognizes that maintaining
one’s personal health is a central component of medical professionalism.94 However, an
important caveat is that the majority of medical school graduates become age-eligible for
colorectal cancer screening several decades following graduation, and so there is a need
to ensure that physicians are continuously exposed to cancer prevention information.
Existing infrastructure in provincial physician health programs could be leveraged to
support specific subgroups of physicians who we identified as having relatively low test
uptake, and reaffirming support for physician health as a core professional value may
help cultivate a more active culture of cancer prevention. Continuous monitoring of
screening compliance will also be important in verifying whether we are deriving the
maximum potential benefit from organized cancer screening programs.

6.2 Strengths and limitations
The primary strength of this study was the use of linked, population-based databases that
contain information on 13.4 million Ontarians who are eligible for universal healthcare.
The use of administrative databases allowed us to avoid the recall and social desirability
biases that are inherent in surveys that rely on self-reported information. Moreover, our
large sample size enabled good precision, and our representative sample makes our
results generalizable to screen-eligible physicians and non-physicians throughout North
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America, and in other countries with access to modern screening technologies.
Additionally, the contemporary nature of the data that was used will enable health system
administrators to design timely and appropriate interventions targeted towards subgroups
of physicians who have suboptimal test uptake.
This study has some limitations. First, the use of administrative healthcare data meant we
were unable to exclude all high-risk individuals including those with a family history of
colon cancer. As well, the use of claims codes did not allow us to discern whether a test
was done for screening purposes or for another reason (colonoscopy in particular may be
performed in response to patient symptoms or unexplained iron-deficiency anemia, for
diagnostic testing, or as a treatment for some other condition), although previously used
claims codes were used when available. To minimize the inclusion of higher risk and
symptomatic individuals, we excluded individuals with a history of invasive colorectal
lesions or anal cancer, inflammatory bowel disease, large bowel or colorectal resection,
or colectomy. Although individuals who completed tests for non-screening indications
would still be considered up-to-date with colon cancer screening, the proportion tested
will overestimate the true screening participation rate for an asymptomatic average-risk
population, which ranges from 50% to 65% in the U.S and Canada. Nonetheless, this
does little to alter our main finding that about one third of physicians and non-physicians
in this screen-eligible cohort were overdue for colorectal cancer screening.
Additionally, our use of OHIP claims did not allow us to discern between flexible
sigmoidoscopies versus incomplete colonoscopies that were terminated at the splenic
flexure, which would have led to an overestimation of flexible sigmoidoscopy uptake,
and an underestimation of colonoscopy uptake. However, we expect the frequency of
incomplete colonoscopies to be low,95 and the effect of this potential limitation is likely
to be small, since uptake of flexible sigmoidoscopy in physicians and non-physicians was
only 1.2% and 1.4%, respectively.
It is also possible that primary care doctors may have easy access to FOBT kits from their
office stock, which could have had a differential impact on FOBT uptake between
physicians and non-physicians, and could have led to an underestimate of testing uptake
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in physicians. However, the impact of this on our estimates is likely minimal. Clinical
expertise and discussions with cancer screening specialists suggested that most
physicians would still submit the test for analysis and interpretation (captured in our
algorithm). Additionally, a positive FOBT would likely lead to an endoscopy procedure
(also captured in our algorithm).
Similar to other observational studies, residual confounding may be impacting our
findings. Specifically, factors such as smoking, alcohol, family history may be impacting
our results, and these factors are either not available or are poorly coded in administrative
data.

6.3 Recommendations for future research
Given the clear benefits of colorectal testing, our study highlights that there is an
opportunity for greater screening participation in physicians, who may in turn positively
influence screening in their patients. Programs that promote recommended health
behaviors in physicians warrant consideration. Physicians are uniquely positioned to
influence preventive health behaviours in their patients, and intuitively, physicians who
practice healthy behaviours may be more effective at counseling their patients to do the
same. This ‘healthy doctor–healthy patient’ effect (‘do as I do’) has been demonstrated
for other preventive health behaviours, including vaccination and screening practices,
exercise, and quitting smoking.19,73,96,97 If a physician feels comfortable to share they
were screened, they may be more believable and motivating to their patients.98,99
Conversely, many physicians report difficulty counseling patients about behaviors they
themselves do not practice.100,101 Interventions aimed at increasing physician and patient
screening uptake could also be evaluated using RCTs. If physicians’ advertise the fact
that they underwent screening (such as through posters in hospital corridors, waiting
rooms) this may encourage patients and other doctors to follow suit, and may increase
physicians’ credibility.
Future studies could also investigate potential barriers to testing within specific
subgroups of physicians, such as those who do not regularly visit primary care
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physicians, and graduates of non-Canadian medical schools. Qualitative research methods
may be warranted to investigate this.

6.4 Conclusion
In summary, our findings highlight that there is an opportunity for physicians to
strengthen their role in colorectal cancer prevention. Healthcare system leaders should
emphasize a culture of disease prevention, including a focus on physician health and
wellness, so that physicians can live healthier lives while providing high quality patient
care. Physicians are uniquely positioned to lead from the front in preventive healthcare,
and we hope that renewed physician leadership in this area will lead to increased
screening uptake among all eligible Canadians.
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Appendix C: Codes used to define colorectal tests.
Outcome
Fecal occult
blood test

Dates
OHIP: 1991 to 3
months ago

Flexible
OHIP: 1991 to 3
sigmoidoscopy months ago

Colonoscopy

OHIP: 1991 to 3
months ago

Codes used in study
OHIP feecode:
Any one of i) to v)
i) L179,
ii) Q152,
iii) L181,
iv) G004,
v) Q133.
OHIP feecode:
Any one of i) to xi) and ABSENCE of the
following 3 codes on the date the code
below is present: E741 or E747 or E705.
i) Z580
ii) Z555
iii) Z491
iv) Z492
v) Z493
vi) Z494
vii) Z495
viii) Z496
ix) Z497
x) Z498
xi) Z499
OHIP feecode:
Any one of i) to x)
i) Z555 and (E741 or E747 or E705)
ii) Z491 and (E741 or E747 or E705)
iii) Z492 and (E741 or E747 or E705)
iv) Z493 and (E741 or E747 or E705)
v) Z494 and (E741 or E747 or E705)
vi) Z495 and (E741 or E747 or E705)
vii) Z496 and (E741 or E747 or E705)
viii) Z497 and (E741 or E747 or E705)
ix) Z498 and (E741 or E747 or E705)
x) Z499 and (E741 or E747 or E705)

Abbreviations: OHIP, Ontario Health Insurance Plan.
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Appendix D: Uptake of colorectal tests in matched physicians and non-physicians: Subgroup analysis by age. *,†

Abbreviations: CI; confidence interval.
*

Uptake was defined by a record of any the following as of April 21, 2016: (i) a fecal occult blood test in the past two years, (ii) flexible sigmoidoscopy in the past five years, or
(iii) colonoscopy in the past 10 years.
† Individuals who received multiple tests during the screening period were counted only once for the composite outcome of fecal occult blood testing, flexible sigmoidoscopy, or
colonoscopy.
‡Prevalence ratios were derived from modified Poisson regression models using generalized estimating equations to account for the correlation structure within matched sets.
§ The P value was calculated using an interaction term in the modified Poisson regression model.
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Appendix E: Uptake of colorectal tests in matched physicians and non-physicians: Subgroup analysis by sex. *,†

Abbreviations: CI; confidence interval.
*

Uptake was defined by a record of any the following as of April 21, 2016: (i) a fecal occult blood test in the past two years, (ii) flexible sigmoidoscopy in the past five years, or
(iii) colonoscopy in the past 10 years.
† Individuals who received multiple tests during the screening period were counted only once for the composite outcome of fecal occult blood testing, flexible sigmoidoscopy, or
colonoscopy.
‡ Prevalence ratios were derived from modified Poisson regression models using generalized estimating equations to account for the correlation structure within matched sets.
§ The P value was calculated using an interaction term in the modified Poisson regression model.
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